Skip to main content
SpringerLink
Log in

Isolated Regional Liver Perfusion in the Treatment of Hepatic Metastases

  • Chapter
Liver Metastasis

Part of the book series: Developments in Oncology ((DION,volume 24))

Abstract

Regional cancer chemotherapy is a means of exploiting dose-response effects by delivering more drug to regionally confined tumors. It is based on the separation of the target organ from the rest of the body since many chemotherapeutic agents display a steep dose-response for toxicity and for therapeutic effect1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Frei E III, Canellos GP. 1980. Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585–594.

    Article  PubMed  Google Scholar 

  2. Southers Research Institute. Informal Reports to the Division of Cancer Treatment of the National Cancer Institute, Birmingham, Alabama, 1971–1982.

    Google Scholar 

  3. Ansfield F, Klotz J, Nealon T, et al. 1977. A Phase III study comparing the clinical utility of four regimens of 5-fluorouracil. A preliminary report. Cancer 39: 34–40.

    Article  PubMed  CAS  Google Scholar 

  4. Healy JE. 1965. Vascular patterns in human metastatic liver tumors. Surg Gynecol Obstet 12: 1187–1193.

    Google Scholar 

  5. Chen HSG and Gross JF. 1980. Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 64: 31–40.

    PubMed  CAS  Google Scholar 

  6. Cady B, Oberfield RA. 1974. Regional infusion chemotherapy of hepatic metastases from carcinoma of the colon. Am J Surg 127: 220–227.

    Article  PubMed  CAS  Google Scholar 

  7. Ansfield IJ, Ramirez G. 1978. The clinical results of 5-fluorouracil intra hepatic arterial infusion in 528 patients with metastatic cancer. In: Ariel IM, ed., Progress in clinical cancer, vol. 7. New York, Grune & Stratton, pp. 201–206.

    Google Scholar 

  8. Huberman MS. 1983. Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma. Semin Oncol 10: 238–248.

    PubMed  CAS  Google Scholar 

  9. Cotino H, Zwaveling A. 1976. Treatment of experimental liver tumors by continuous intra-arterial chemotherapy. Eur J Cancer 12: 177–180.

    Article  PubMed  CAS  Google Scholar 

  10. Grage TB, Vassipoulos PP, Shingleton WW, et al. 1979. Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer. A central Oncology Group study. Surgery 86: 550–555.

    PubMed  CAS  Google Scholar 

  11. Davis HL. 1982. Chemotherapy of large bowel cancer. Cancer 50: 2638–2646.

    Article  PubMed  CAS  Google Scholar 

  12. Sullivan RD and Zurek WZ. 1965. Chemotherapy for liver cancer by protacted ambulatory infusion. JAMA 194: 481–486.

    Article  PubMed  CAS  Google Scholar 

  13. Brennan MJ, Talley RW, Drake EH et al. 1967. 5-Fluoroura- cil treatment of liver metastases by continuous hepatic artery infusion via Cournand Catheter. Ann Surg 158: 405- 419.

    Google Scholar 

  14. Burrows JH, Talley RW, Drake et al. 1967. Infusion of fluorinated pyrimidines into hepatic artery for treatment of metastatic carcinoma of the liver. Cancer 20: 1886–1892.

    Article  PubMed  CAS  Google Scholar 

  15. Watkins E Jr, Khazei AM, Nahra KS. 1970. Surgical basis for arterial infusion chemotherapy and disseminated carcinoma of the liver. Surg Gynecol Obstet 130: 580–605.

    Google Scholar 

  16. Massey WH, Fletcher WS, Judkins MP, et al. 1971. Hepatic artery infusion for metastatic malignancy using percutaneously placed catheters. Am J Surg 121: 160–164.

    Article  PubMed  CAS  Google Scholar 

  17. Freckman HA. 1971. Chemotherapy for metastatic colorectal liver carcinoma by intra-aortic infusion. Cancer 28: 1152–1160.

    Article  PubMed  CAS  Google Scholar 

  18. Tandon RN, Bunnell IL, Copper RG. 1973. The treatment of metastatic carcinoma of the liver by the percutaneous selective hepatic artery infusion of 5-fluorouracil. Surgery 73: 118–121.

    PubMed  CAS  Google Scholar 

  19. Buroker T, Samson M, Correa J, et al. 1976. Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. Cancer Treat Rep 60: 1277–1279.

    PubMed  CAS  Google Scholar 

  20. Ariel IM, Padula G. 1978. Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by intra-arterial administration of chemotherapy and radioactive isotopes. In: Ariel IM, ed., Progress in clinical cancer, vol. 7. New York, Grune & Stratton, pp. 247–254.

    Google Scholar 

  21. Petrek JA, Minton JP. 1979. Treatment of hepatic metastases by percutaneous hepatic arterial infusion. Cancer 43: 2182–2188.

    Article  PubMed  CAS  Google Scholar 

  22. Reed ML, Vaitkevicus VK, Al-Sarraf M, et al. 1981. The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: Ten year results of 124 patients in a prospective protocol. Cancer 47: 402–409.

    Article  PubMed  CAS  Google Scholar 

  23. Smiley S, Schouten J, Chang A, et al. 1981. Intra hepatic infusion with 5-FU for liver metastases of colorectal carcinoma. Proc Am Soc Clin Oncol 22: 391.

    Google Scholar 

  24. Ensminger W, Niederhuber J, Gyves J, et al. 1982. Effective control of liver metastases from colon cancer with an implanted system for hepatic arterial chemotherapy. Proc Am Soc Clin Oncol 1: 94.

    Google Scholar 

  25. Balch CM, Urist MM, Soong SJ, McGregor M. 1983. A prospective Phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg 198: 567–573.

    Article  PubMed  CAS  Google Scholar 

  26. Jaffe BM, Donegan WL, Watson F, et al. 1968. Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 127: 1–11.

    PubMed  CAS  Google Scholar 

  27. Bengmark S, Hafstrom L. 1969. The natural history of primary and secondary malignant tumors of the liver. 1. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 23: 198–202.

    Article  PubMed  CAS  Google Scholar 

  28. Howell SB, Wung WE, Taetle R, et al. 1981. Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer 48: 1281–1289.

    Article  PubMed  CAS  Google Scholar 

  29. Martin DS, Stolfi RL, Swayer RC, et al. 1982. High-Dose 5-Fluorouracil with delayed Urine ’Rescue’ in Mice. Cancer Res 42: 3964–3670.

    PubMed  CAS  Google Scholar 

  30. Rubin J, Purvis J, Britell JC, et al. 1981. Phase II study of PALA in advanced large bowel carcinoma. Cancer Treat Rep 65:• 335–336.

    Google Scholar 

  31. Ardalan B, Jamin D, Jayaram HN, Presant CA. 1984. Phase I study of continuous infusion PALA and 5-FU. Cancer Treat Rep 68: 531–534.

    PubMed  CAS  Google Scholar 

  32. Cadman F, Davis L, Heimer R. 1979. Enhanced 5-fluorouracil nucleotide formation following methotrexate: Biochemical explanation for drug synergism. Science 205: 1135–1137.

    Article  PubMed  CAS  Google Scholar 

  33. Browman GP. 1984. Clinical application of the concept of Methotrexate Plus 5-FU Sequence Dependent. ’Synergy’. How good is the Evidence? Cancer Treat Rep 68: 465–470.

    CAS  Google Scholar 

  34. Ensminger WD, Gyves JW. 1984. Regional cancer chemotherapy. Cancer Treat Rep 68: 101–115.

    PubMed  CAS  Google Scholar 

  35. Ramming KP, Sparks FC, Eilbert FR, et al. 1976. Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. Am J Surg 132: 236–242.

    Article  Google Scholar 

  36. Iwaki A, Nagasue N, Kobayoshi M, et al. 1978. Intraarterial chemotherapy with concomitant use of vasoconstrictors for liver cancer. Cancer Treat Rep 62: 145–146.

    PubMed  CAS  Google Scholar 

  37. Dakhil S, Ensminger W, Cho K, et al. 1982. Improved regional selectivity of hepatic arterial BCNU with degradable microspheres. Cancer 50: 631–635.

    Article  PubMed  CAS  Google Scholar 

  38. Boddie AW Jr, Booker L, Mullins JD, et al. 1979. Hepatic hyperthermia by total isolation and regional perfusion in vivo. J Surg Res 26: 447–457.

    Article  PubMed  Google Scholar 

  39. Van de Velde CJH, Kothuis BJL, Barenbrug HWM, et al. 1984. A successful technique of in vivo isolated chemotherapeutic liver perfusion in the pig with survival. Submitted for publ. J Surg Res.

    Google Scholar 

  40. Tjaden UR, De Bruin EA, Van de Velde CJH, et al. 1984. Determinations of 5-Fluorouracil and related compounds by High Performance Liquid Chromotography. Submitted for publ. J Chromatogr Biomed Appl.

    Google Scholar 

  41. Ramirez G, Ansfield FJ. 1982. Chemotherapy of liver metastases. In: Weiss L, Gilbert HA, Hall GK, eds., Boston, Med Publ, pp. 348–359.

    Google Scholar 

  42. Ansfield FJ, Curreri AR. 1959. Further clinical studies with 5-fluorouracil. J Natl Cancer Inst 22: 497–507.

    PubMed  CAS  Google Scholar 

  43. Curreri AR, Ansfield FJ, Mclver FA, et al. 1958. Clinical studies with 5-fluorouracil. Cancer Res 18: 478–484.

    PubMed  CAS  Google Scholar 

  44. Vaitkevicus VK, Brennan MJ, Bechet VL, et al. 1961. Clinical evaluation of cancer chemotherapy with 5-fluorouracil. Cancer 14: 131–152.

    Article  Google Scholar 

  45. Danenberg PV, Langenbach RJ, Heidelberger C. 1974. Structures of reversible and irreversible complexes of thymidilate synthetase and fluorinated pyrimidine nucleotides. Biochemistry 13: 926–933.

    Article  PubMed  CAS  Google Scholar 

  46. Everson R, Kessel D, Hall T. 1970. Enzymatic determinants of responsiveness of the LPC-1 plasma cell neoplasm to fluorouracil and fluorodeoxyuridine. Biochem Pharmacol 19: 2932–2934.

    Article  PubMed  CAS  Google Scholar 

  47. Kessel D, Hall T, Reyes P. 1969. Metabolism of uracil and 5-fluorouracil in P-388 murine leukemia cells. Mol Pharmacol 5: 481–486.

    PubMed  CAS  Google Scholar 

  48. Kessel D, Wodinsky I. 1969. Thymidine kinase as a determinant of the response to 5-fluoro-2-deoxyuridine in transplantable murine leukemias. Mol Pharmacol 6: 251–254.

    Google Scholar 

  49. Nahas A, Savlov ED, Hall TC. 1974. Phosphoribosyltransferase in colon tumor and normal mucosa as an aid in adjuvant chemotherapy with 5-FU. Cancer Chemother Rep 58: 909–912.

    PubMed  CAS  Google Scholar 

  50. Reyes P, Hall TC. 1969. Synthesis of 5-fluorodeoxyuridine 5’-phosphate a pyrimidine phosphoribosyltransferase of mammelian origin. II. Correlation between tumor levels of the enzyme and the 5-fluorouracil-promoted increase in survival of tumorbearing mice. Biochem Pharmacol 18: 2587–2590.

    Article  PubMed  CAS  Google Scholar 

  51. Klubes P, Connelly K, Cerna I, Mandel H. 1978. Effects of 5-fluorouracil on 5-fluorodeoxyuridine 5’-monophosphate and 2-deoxyuridine 5’-monophosphate pools, and DNA synthesis in solid mouse L1210 and rat Walker 256 tumors. Cancer Res 38: 2325–2331.

    PubMed  CAS  Google Scholar 

  52. Myers CE, Young RC, Chabner BA. 1976. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal muco sa and tumor. Cancer Res 36: 1653–1658.

    PubMed  CAS  Google Scholar 

  53. Ardalan B, Buscaglia M, Schein PS. 1978. Tumor 5-fluorodeoxyridilate concentration as a determinant of 5-fluoro- uracil response. Biochem Pharmacol 27: 2009–2013.

    Article  PubMed  CAS  Google Scholar 

  54. Myers CE, Young RC, Chabner BA. 1975. Biochemical determinants of 5-fluorouracil in vivo: the role of deoxyuridilate pool expansion. J Clin Invest 56: 1231–1238.

    Article  PubMed  CAS  Google Scholar 

  55. Myers CE, Young RC, Johns DG, Chabner BA. 1974. Assay of 5-fluorodeoxyuridine 51-monophosphate and deoxyuridine monophosphate pools following 5-fluorouracil. Cancer Res 34: 2683–2688.

    Google Scholar 

  56. Wilkinson DS, Pitot HC. 1973. Inhibition of ribisomal ribonucleic acid maturation in Novikoff hepatoma cells by 5-fluorouracil and 4-fluorouridine. J Biol Chem 248: 63–68.

    PubMed  CAS  Google Scholar 

  57. Wilkinson DS, Tisty TD, Hanas RJ. 1975.The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine. Cancer Res 35: 3014–3020.

    PubMed  CAS  Google Scholar 

  58. Mandel HG. 1981. The target cell determinants of the antitumor actions of 5-FU: DoesFU incorporation into RNA play a role? Cancer Treat Rep 65: 63–71.

    PubMed  CAS  Google Scholar 

  59. Chaudhuri NK, Mukherjee KL, Heidelberger C. 1958. Studies of fluorinated pyrimidines (VII): the degradative pathway Biochem Pharmacol 1: 328–341.

    Google Scholar 

  60. Mukherjee KL, Boohar J, Wentland D. 1963. Studies on fluorinated pyrimidines (XVI). Metabolism of 5-fluoroura- cil-2-C14 and 5-fluoro-2’-deoxyuridine-2-C14 in cancer patients. Cancer Res 23: 39–66.

    Google Scholar 

  61. Sadee W, Wong CG. 1977. Pharmacokinetics of 5-fluorouracil: inter-relationship with biochemical kinetics in moni toring therapy. Clin Pharmacokinet 2: 437–450.

    Article  PubMed  CAS  Google Scholar 

  62. Stone RT, Jabour A, Wilson SE, Rangel DM. 1980. Uptake of 5-fluorouracil during isolated perfusion of the canine liver. J Surg Oncol 13: 347–353.

    Article  PubMed  CAS  Google Scholar 

  63. Aigner K, Walther H, Tonn J, et al. 1983. First experimen tal and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary. In: Rentchnick P, Senn HJ, eds., Recent results in cancer research, vol. 86. Berlin, Springer Verlag, pp. 99–102.

    Google Scholar 

  64. Aigner KR, Tonn JC, Walther H, et al, 1984. The isolated liver perfusion technique for high-dose chemotherapy of metastases from colorectal cancer. Two years’ clinical experience. In: Van de Velde CJH, Sugarbaker PH, eds., Liver metastasis. The Hague, Martinus Nijhoff, Chapter 29

    Google Scholar 

Download references

Authors
  1. C. J. H. van de Velde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. R. Tjaden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. J. L. Kothuis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, University Hospital, Leiden, The Netherlands

    Cornelis J. H. Van De Velde MD, PhD

  2. Colorectal Cancer Section, National Institutes of Health, Bethesda, Maryland, USA

    Paul H. Sugarbaker MD

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Martinus Nijhoff Publisher, Dordrecht

About this chapter

Cite this chapter

van de Velde, C.J.H., Tjaden, U.R., Kothuis, B.J.L. (1984). Isolated Regional Liver Perfusion in the Treatment of Hepatic Metastases. In: Van De Velde, C.J.H., Sugarbaker, P.H. (eds) Liver Metastasis. Developments in Oncology, vol 24. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-6051-0_25

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-6051-0_25

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-009-6053-4

  • Online ISBN: 978-94-009-6051-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation